Rising JCV-Ab index during natalizumab therapy for MS
Inauspicious for a highly efficacious drug
Citation Manager Formats
Make Comment
See Comments

Infection with JC virus (JCV) is not noticeable and is usually inconsequential. Natalizumab therapy, however, blocks the very late antigen-4 adhesion molecule on immune cells, preventing them from attaching to vascular cell adhesion molecule-1 on brain endothelial cells and then penetrating into the CNS. The dearth of T cells, and perhaps other factors, allows JCV to infect oligodendroglia and cause progressive multifocal leukoencephalopathy (PML), at a risk of 1/1,000 per year. In this issue of Neurology® Neuroimmunology & Neuroinflammation, Schwab et al.1 find that natalizumab markedly increases levels of the JCV antibodies that may foretell the risk of PML.
Footnotes
Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms.
- © 2016 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Progressive multifocal leukoencephalopathy after fingolimod treatmentJoseph R. Berger, Bruce A. Cree, Benjamin Greenberg et al.Neurology, April 18, 2018 -
Article
Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysisDavid Bargiela, Matthew T. Bianchi, M. Brandon Westover et al.Neurology, January 13, 2017 -
Views & Reviews
Natalizumab-associated PMLChallenges with incidence, resulting risk, and risk stratificationNicholas Schwab, Tilman Schneider-Hohendorf, Nico Melzer et al.Neurology, February 22, 2017 -
Views & Reviews
Reactivation of JC virus and development of PML in patients with multiple sclerosisK. Khalili, M. K. White, F. Lublin et al.Neurology, March 26, 2007